Xeris Biopharma Holdings Inc(XERS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 7:03 AM ET (Korea 10/28 20:03)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.1 | Insider Own | 5.05% | Shs Outstand | 173.6M | Perf Week | -6.11% |
| Market Cap | 1.91B | Forward P/E | 30.35 | EPS next Y | 6785.72% | Insider Trans | -4.03% | Shs Float | 173.1M | Perf Month | 6.31% |
| Enterprise Value | 2.07B | PEG | - | EPS next Q | 0.03 | Inst Own | 60.14% | Short Float | 4.64% | Perf Quarter | 24.7% |
| Income | -0.02B | P/S | 5.68 | EPS this Y | 55.91% | Inst Trans | 1.92% | Short Ratio | 3.49 | Perf Half Y | 71.59% |
| Sales | 0.34B | P/B | - | EPS next 5Y | - | ROA | -4.6% | Short Interest | 8.03M | Perf YTD | 33.12% |
| Book/sh | -0.06 | P/C | 15.65 | EPS past 3/5Y | - | ROE | - | 52W High | -8.45% ($11.41) | Perf Year | 12.24% |
| Cash/sh | 0.67 | P/FCF | 34.22 | Sales past 3/5Y | 38.33% 70.2% | ROIC | -8.19% | 52W Low | 99.05% ($5.25) | Perf 3Y | 549.07% |
| Dividend Est. | - | EV/EBITDA | 41.96 | EPS Y/Y TTM | 54.68% | Gross Margin | 83.34% | Volatility(W/M) | 4.41% 5.73% | Perf 5Y | 471.04% |
| Dividend TTM | - | EV/Sales | 6.18 | Sales Y/Y TTM | 36.33% | Oper. Margin | 10.91% | ATR (14) | 0.51 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.02 | EPS Q/Q | -1387.6% | Profit Margin | -5.12% | RSI (14) | 57.27 | Recom | 1.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.45 | Sales Q/Q | 28.74% | SMA20 | 2.32% ($10.21) | Beta | 0.84 | Target Price | $12.86 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/5 | SMA50 | 13.69% ($9.19) | Rel Volume | 0.66 | Prev Close | $10.21 |
| Employees | 435 | LT Debt/Eq | - | EPS/Sales Surpr. | -1587.6% 2.19% | SMA200 | 40.18% ($7.45) | Avg Volume(3M) | 2.30M | Price | $10.45 |
| IPO | 2018/6/21 | Option/Short | Yes/Yes | Trades | 9832 | Volume | 1,521,752 | Change | 2.35% |
💉 Xeris Biopharma (XERS) is a US specialty pharmaceutical company focused on endocrine, diabetes, and rare disease areas. Leveraging its proprietary formulation technology that makes injectable medicines stable and ready-to-use at room temperature, the company markets three commercial products: Gvoke, a treatment for severe hypoglycemia; Keveyis, a treatment for primary periodic paralysis; and Recorlev, a treatment for endogenous Cushing's syndrome.
Over the past 1 year, on the higher side
8% below its 1-year high.
Traded less than usual. That is 66% of its average volume.
Next earnings report: November 5
8 days to go.
XERS keeps an operating profit but posts a net loss
Of every $100 in sales, $10.91 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +55.9% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $568. Peers typically go for $154.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +471.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 60.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #26 of 83 in the industry
Based on market cap of $2B.
BCRX#24 Biocryst Pharmaceuticals Inc $2B PER - 
TRLV#25 Trulieve Cannabis Corp $2B PER - XERS#26 Xeris Biopharma Holdings Inc $2B PER - 
ALVO#27 Alvotech $2B PER - 
ANIP#28 ANI Pharmaceuticals Inc $2B PER 15.4 
FAQ
What kind of company is XERS?
XERS belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of XERS?
The market cap of XERS is approximately $1.9B, ranking 2,098 within its sector.
What is the 52-week high and low for XERS?
XERS has recorded a 52-week high of $11.41 and a low of $5.25.
